Ningbeituo^® Urapidil Hydrochloride Injection is a selective α1-adrenergic receptor antagonist that exerts both central and peripheral blood pressure-lowering effects. It is widely used to manage hypertensive emergencies, severe and malignant hypertension, resistant hypertension, as well as perioperative hypertension. Approved in June 2023 as a chemical drug under Category 4, Ningbeituo® is included in China’s National Reimbursement Drug List (Category B). Administered via intravenous injection, Ningbeituo^® Urapidil Hydrochloride Injection acts within 30 seconds, achieving rapid, stable, and controllable blood pressure reduction without increasing intracranial pressure or significantly affecting heart rate. Its unique organ-protective properties make it a first-line treatment for hypertensive emergencies in clinical practice.